# Vir Biotechnology Shares Rise Nearly 10% in Premarket After Gilead Deal

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/31825
Published: 2026-10-14T13:15:33.000Z
Updated: 2026-10-14T13:15:33.000Z
Section: Business

> Gilead will use Vir’s PRO-XTEN platform to discover and develop cancer drugs under an agreement valued at up to nearly $1.9 billion.

Vir Biotechnology shares traded nearly 10% higher in premarket trading on Oct. 14 after the company announced a licensing agreement with Gilead to use its PRO-XTEN platform for cancer drug discovery and development.

The agreement is valued at up to nearly $1.9 billion. Gilead will use Vir’s masking technology platform to discover and develop cancer drugs.